Trial Profile
A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 May 2022
Price :
$35
*
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 30 Apr 2021 Status changed from active, no longer recruiting to completed.
- 03 Mar 2021 Planned End Date changed from 28 Apr 2021 to 21 Apr 2021.
- 03 Mar 2021 Planned primary completion date changed from 28 Apr 2021 to 21 Apr 2021.